Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Olmesartan franchise

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Olmesartan franchise was produced by Daiichi Sankyo.

In virtual meeting, CHMP backs Sanofi’s myeloma drug Sarclisa

In virtual meeting, CHMP backs Sanofi’s myeloma drug Sarclisa popular with patients and bolster its franchise. ... Sarclisa is one of a clutch of drugs the French drugmaker has developed to try to rebuild its once-mighty oncology franchise after falling behind in the category in recent years,

Pfizer eyes 20-strain Prevnar filing this year, after phase 3 win

Pfizer eyes 20-strain Prevnar filing this year, after phase 3 win before the end of the year, as it tries to protect its franchise from Merck &Co’s rival shot. ... of the franchise in adults, an area where Prevnar 13 has been failing back.

J&J aims for US approval of MS drug ponesimod

J&J aims for US approval of MS drug ponesimod If approved, ponesimod will compete directly with Novartis’ S1P receptor modulator franchise, which includes Gilenya (fingolimod) and follow-up Mayzent (siponimod), which is approved for secondary progressive forms of MS only

Staying ahead in the era of precision medicine

Staying ahead in the era of precision medicine to our advisory board Co-Chair Dr Zhen Su, Head of Merck KGaA’s global oncology franchise.

20 for 2020 – Five pharma leaders to watch in 2020

20 for 2020 – Five pharma leaders to watch in 2020 and Braftovi) that Pfizer thinks could become a top industry franchise in colorectal cancer when combined with antibody drug cetuximab. ... to 2025 built on the Prevnar franchise, rare disease therapy Vyndaqel (tafamidis), breast cancer therapy Ibrance

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Nucleus Global

Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 700 experts delivering world-class...

Latest intelligence

Has the pandemic opened up a future of accelerated diagnosis and better care for rare disease patients?
The challenge with rare disease is in the name – it's rare, so awareness is limited and diagnosis hindered. Could a more virtual existence change this? A Medical Affairs viewpoint...
The other side of … blood cancer
To stay motivated for the fight, some patients need to feel like active players in the treatment journey, not passengers to every decision....
COVID clinical trial
COVID-19 – a catalyst for technology adoption in clinical trials
As the COVID-19 crisis disrupts clinical trials around the globe, it is also proving to be a catalyst that may transform its approach to trials for good...

Infographics